Alembic Ltd
NSE: ALEMBICLTD BSE: 506235
₹91.72
(0.64%)
Tue, 03 Mar 2026, 02:17 pm
Market Cap23.51B
PE Ratio7.39
Dividend2.62
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1907
- Incorporated at Vadodara.
1938
- Authorised capital Rs 20 lakhs with 10,000 6 1/4% preference and 10,000 equity shares; issued 5,000 preference and all equity.
1942
- Issued 5,000 6% preference shares.
1944
- Increased authorised capital to Rs 50 lakhs with 30,000 shares; issued 3,000 equity shares in 3:10 proportion.
1946
- Issued 2,000 equity shares as rights at Rs 150 premium in 2:13 proportion.
1947
- Converted 5,000 unclassified shares to equity issued as rights at Rs 150 premium in 1:3 proportion.
1948
- Converted 5,000 unclassified shares to equity issued as bonus in 1:4 proportion.
1949
- Increased authorised capital to Rs 1 crore with 5,000 6% third preference and 45,000 unclassified shares.
- Converted 7,000 unclassified shares to equity issued as bonus in 2:3 proportion.
1958
- Authorised capital Rs 10,000,000; issued and paid-up Rs 8,000,000 as at 31 December.
1959
- Offered 20,000 right equity shares at par in 1:4 proportion.
1961
- Offered 10,000 right equity shares at par in 1:1 proportion.
1962
- Issued 9,500 bonus equity shares in 1:10 proportion.
- Offered 40,000 right equity shares at Rs 30 premium in 4:11 proportion.
1966
- Issued 48,167 bonus equity shares in 1:3 proportion in December.
- Issued 12,278 equity shares to members of Alembic Distributors Ltd and Alembic Distributing Agency on merger.
1967
- High Courts sanctioned amalgamation of Alembic Distributors Ltd effective 1 January.
1968
- Issued 25,080 right equity shares at par in 5:41 proportion.
1971
- Issued 57,487 right equity shares at par in 1:5 proportion in March.
1977
- Converted 6 1/4% and 6% III preference shares to 9% redeemable from 1 Jan 1976.
- Redeemed 5,000 5% preference shares at Rs 105 on 1 Jan.
1979
- Issued 75,000 secured debentures of Rs 100 each as rights.
1980
- Redeemed 1,000 preference shares on 1 Jan 1978, 1 Jan 1979, 1 Nov 1980, 1 Jan 1981, 1 Jan 1982, 1 Jan 1983.
1985
- Redeemed 2,000 preference shares.
- Allotted 66,900 equity shares to Neomer Ltd shareholders on merger.
1986
- High Court of Gujarat approved Neomer Ltd amalgamation effective 1 January 1983.
1989
- Introduced Feed Supplements and Tonics products.
- Started Panpharm Division at Panelav, Gujarat for formulations.
1990
- Introduced Ciprofloxacin.
- Veterinary division introduced ascal, ruman bolus and other products.
- Introduced ginseng, zinc and vitamin-B complex preparations.
- Issued 100,000 14% non-convertible debentures redeemable from 1995.
1991
- Developed Roxithromycin bulk drug.
1992
- Introduced Cloxacillin Amoxicillin injections in veterinary division.
1993
- Expanded Penicillin capacity to 1000 MMU with effluent treatment plant and diesel compressors.
- Introduced Azithromycin antibiotic.
1995
- Proposed gas turbine captive co-generation power unit at Rs 25 crores.
- Installed two large penicillin fermentors.
- Issued 164,732 equity shares at Rs 850 premium on rights basis.
1996
- Allotted 1,000,000 preference shares on preferential basis.
1997
- Introduced Nimegesic Gel.
- Introduced Rorid Roxithromycin liquid for paediatric use.
- Launched Clarithro and basic manufacture of clarithromycin.
- Installed Penicillin 600 MMU/annum and Erythromycin 100 TPA capacities with second extraction facility.
- Launched Alembic Herbals veterinary division.
- Issued 1,000,000 16% redeemable non-convertible cumulative preference shares.
- Launched Rofecoxib and Celecoxib.
2000
- Launched Glycodin Activ Cold & Flu Tablets.
2001
- Launched 'Asigra' sildenafil citrate in 25 mg and 50 mg dosages.
- Launched OTC Glycodin Activ cold and flu tablets.
2002
- Gujarat High Court sanctioned merger of Darshak Ltd Bulk Drug unit.
- Entered in-licensing pact with Euroresearch for Gelfix Collagen dressing sponge pads.
- Appointed Nitin Jaywant as President, Active Pharmaceutical Ingredients division.
- Launched 'SynX' division for Syndrome X.
- Entered research pact with Chiron Corporation.
- Received DCGI approval for Cefetamet Pivoxil tablets.
- Tied up with Euroresearch for product introduction in India.
2003
- Launched Cefepime, 4th generation injectable Cephalosporin.
- Allotted equity shares to Darshak Ltd shareholders per demerger scheme.
- Acquired brand and trademark rights of Yutopar from Solvay Pharmaceuticals.
- Launched BioArc Research Solutions for R&D services.
- Entered speciality therapeutics segment.
- Signed R&D agreements with two MNC companies.
- Announced rights issue of Rs 32.37 crores.
- Raised Rs 10 crore through 90-day commercial paper.
- Signed MoU with Xechem International.
2005
- Launched no-calorie sugar substitute 'Zero'.
2006
- Split face value of shares from Rs 10 to Rs 2.
2008
- Acquired API manufacturing unit of Nirayu Pvt Ltd at Panelav, Gujarat.
2009
- Recommended 20% dividend.
2010
- Appointed Milin Mehta as Additional Independent Director.
2011
- Appointed Ashok Tulankar as Vice President - Production, Additional Director and Whole-Time Director.
2012
- Appointed Chandrashekhar P. Buch as Additional Non-Executive Independent Director.
2013
- Allotted 13,35,15,914 bonus equity shares in 1:1 ratio.
- Appointed R. C. Saxena as Additional Non-Executive Independent Director.
- Recommended dividend of Re. 0.20 (10%) per equity share of Rs. 2.
2014
- Recommended dividend of Re. 0.15 (7.5%) per equity share of Rs. 2.
2018
- HGS won NASSCOM Customer Service Excellence Award 2018 in Transformation Category.
2020
- Received USFDA approval for generic ophthalmic solution.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800